Current understanding of rheumatoid arthritis therapy

I Colmegna, BR Ohata… - Clinical Pharmacology & …, 2012 - Wiley Online Library
Progress in understanding the cellular and molecular mechanisms of rheumatoid arthritis (RA),
together with the availability of new therapies, has changed the way we think about RA. …

Telomerase insufficiency in rheumatoid arthritis

H Fujii, L Shao, I Colmegna… - Proceedings of the …, 2009 - National Acad Sciences
In rheumatoid arthritis (RA), chronically stimulated T lymphocytes sustain tissue-destructive
joint inflammation. Both naïve and memory T cells in RA are prematurely aged with …

HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations

I Colmegna, R Cuchacovich… - Clinical microbiology …, 2004 - Am Soc Microbiol
Current evidence supports the concept that reactive arthritis (ReA) is an immune-mediated
synovitis resulting from slow bacterial infections and showing intra-articular persistence of …

Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis

L Shao, H Fujii, I Colmegna, H Oishi… - Journal of Experimental …, 2009 - rupress.org
In rheumatoid arthritis (RA), dysfunctional T cells sustain chronic inflammatory immune
responses in the synovium. Even unprimed T cells are under excessive replication pressure, …

A proinflammatory secretome mediates the impaired immunopotency of human mesenchymal stromal cells in elderly patients with atherosclerosis

…, S Nadeau, F Rodier, I Colmegna - Stem cells …, 2017 - academic.oup.com
Inflammation plays a pivotal role in the initiation and progression of atherosclerosis (ATH).
Due to their potent immunomodulatory properties, mesenchymal stromal cells (MSCs) are …

Autoimmune sensorineural hearing loss: the otology–rheumatology interface

T Mijovic, A Zeitouni, I Colmegna - Rheumatology, 2013 - academic.oup.com
Autoimmune sensorineural hearing loss (SNHL) is a rare clinical entity characterized by a
progressive fluctuating bilateral asymmetric SNHL that develops over several weeks to months…

Systematic review of recommendations on the use of disease‐modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer

MA Lopez‐Olivo, I Colmegna… - Arthritis Care & …, 2020 - Wiley Online Library
Objective To evaluate consensus recommendations regarding management of rheumatoid
arthritis ( RA ) in patients with cancer. Methods We searched electronic databases, guideline …

[HTML][HTML] Human multipotent mesenchymal stromal cells cytokine priming promotes RAB27B-regulated secretion of small extracellular vesicles with immunomodulatory …

…, M Lora, D Shum-Tim, J Rak, I Colmegna - Stem Cell Research & …, 2020 - Springer
Background The paracrine effects of multipotent mesenchymal stromal cells (MSCs) are
mediated by their secretome composed by soluble factors (ie, cytokines, growth factors, …

Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis

I Colmegna, A Diaz‐Borjon, H Fujii… - Arthritis & …, 2008 - Wiley Online Library
Objective In rheumatoid arthritis (RA), telomeres of lymphoid and myeloid cells are age‐inappropriately
shortened, suggesting excessive turnover of hematopoietic precursor cells (…

ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis

…, P Deshpande, S Pryshchep, I Colmegna… - The Journal of …, 2009 - journals.aai.org
Immune responses to citrullinated neoantigens and clinical efficacy of costimulation blockade
indicate a general defect in maintaining T cell tolerance in rheumatoid arthritis (RA). To …